“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion”, J of Skin, vol. 3, p. S31, Nov. 2019, doi: 10.25251/skin.3.supp.31.